105 related articles for article (PubMed ID: 1686602)
21. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
22. Interaction of cyclosporin A and etoposide. Clinical and in vitro assessment in blast phase of chronic myeloid leukaemia.
Maia RC; Noronha H; Vasconcelos FC; Rumjanek VM
Clin Lab Haematol; 1997 Sep; 19(3):215-7. PubMed ID: 9352149
[TBL] [Abstract][Full Text] [Related]
23. Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Kashimura M; Ohyashiki K
Leuk Res; 2010 Aug; 34(8):e213-4. PubMed ID: 20299093
[No Abstract] [Full Text] [Related]
24. Long duration priapism in blast crisis of chronic myeloid leukemia.
Dogra PN; Kumar P; Goel R; Dash SC
J Assoc Physicians India; 2004 Feb; 52():170. PubMed ID: 15656063
[No Abstract] [Full Text] [Related]
25. Splenomegaly and hepatomegaly at onset of blastic crisis in chronic myeloid leukaemia have prognostic importance.
Parikh PM; Charak BS; Banavali SD; Koppikar SB; Giri NK; Kumar A; Saikia TK; Gopal R; Mazumdar AT; Advani SH
J Assoc Physicians India; 1988 Nov; 36(11):653-5. PubMed ID: 3248993
[No Abstract] [Full Text] [Related]
26. [Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Savchenko VG; Isaev VG; Abakumov EM; Khoroshko ND; Turkina AG; Sokolov AN; Viadro MM; Navashin SM
Antibiot Khimioter; 1992 Jul; 37(7):47-9. PubMed ID: 1456812
[TBL] [Abstract][Full Text] [Related]
27. Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia.
Preisler HD; Raza A; Baccarani M
Leuk Lymphoma; 1993; 11 Suppl 1():303-6. PubMed ID: 7504547
[TBL] [Abstract][Full Text] [Related]
28. The combined use of busulfan and hydroxyurea in the treatment of chronic myeloid leukemia.
Jim RT
Hawaii Med J; 1990 Apr; 49(4):133-4. PubMed ID: 2341244
[No Abstract] [Full Text] [Related]
29. Survival in chronic myeloid leukemia.
Malhotra H
J Assoc Physicians India; 1994 Apr; 42(4):345. PubMed ID: 7619118
[No Abstract] [Full Text] [Related]
30. Two siblings with chronic myelogenous leukemia.
Kapsali E; Tsiara S; Christou L; Panteli A; Bourantas KL
J Exp Clin Cancer Res; 2000 Dec; 19(4):541-3. PubMed ID: 11277336
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies.
Galski H; Sivan H; Lazarovici P; Nagler A
Leuk Res; 2006 Sep; 30(9):1151-8. PubMed ID: 16542724
[TBL] [Abstract][Full Text] [Related]
32. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
33. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
34. [Chronic leukemia].
Shibata A; Narita M
Gan To Kagaku Ryoho; 1989 May; 16(5):1982-8. PubMed ID: 2658837
[TBL] [Abstract][Full Text] [Related]
35. Mini-ice protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
Carella AM
Leuk Lymphoma; 2001 Jan; 40(3-4):447-8. PubMed ID: 11426572
[No Abstract] [Full Text] [Related]
36. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
[TBL] [Abstract][Full Text] [Related]
37. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia.
Suttorp M; Rister M; Schmitz N
Med Pediatr Oncol; 1994; 22(5):358-9. PubMed ID: 8127262
[No Abstract] [Full Text] [Related]
38. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
39. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
40. Aggregates of pseudo-Gaucher cells after treatment of chronic myeloid leukemia in blastic phase.
Helbig G; Janikowska A; Kyrcz-Krzemien S
Int J Hematol; 2015 Jan; 101(1):3-4. PubMed ID: 25380681
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
